Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge

Amneal Pharmaceuticals, Inc.

Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.
Settlement covers direct purchaser, indirect purchaser, and individual claims in MDL.
Company to record pre-tax charge of approx. $265M in Q2 2022.
Payments to be made between 2022 and Jan 2024; funded by cash on hand, cash flow, and revolver.
Settlement is not an admission of liability; subject to court approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.